6 / 7
allied
academies
Page 26
Virology Research Journal
Volume 1 Issue 4
Notes:
Vaccines World 2017
November 09-10, 2017 Vienna, Austria
21
st
World Congress and Exhibition on
VACCINES, VACCINATION & IMMUNIZATION
Anissa Boumlic-Courtade, Virol Res J 2017, 1:4
Accelerating vaccine process development
and manufacturing: Innovative approaches
and challenges
P
reventable diseases vaccines save millions of lives
but are not always delivered when needed to a
large fraction of the population. In addition, there are
several infectious diseases that remain without cure
or vaccine. Innovations in process development and
manufacturing are unavoidable to enable release of
existing and novel vaccines and their delivery where
and when they are mostly needed. This presentation will
outline where innovative approaches and technologies
while developing and/or optimizing the process and
at manufacturing scale can accelerate clinical phases
and compress the time to market of highly needed
vaccines. Furthermore, using case studies like Ebola
and influenza outbreaks, challenges will also be
highlighted in pandemic situations and approaches
will be discussed on how to alleviate roadblocks and
be better prepared to manufacture vaccines in urgent
situations.
Biography
Anissa Boumlic-Courtade PhD is the Associate Director for the vaccine initiative
in EMEA with Merck. She joined Merck in 2009 (formerly Millipore) after research
experience in various institute including Pasteur Institute of Athens and the CNRS
(National Center for Research, France). She has held various positions focused
on downstream processing, virus safety, monoclonal antibody, vaccine process
development and manufacturing. She holds a MSc in Biotechnology Engineering
from the Ecole Supérieure de Biotechnologie (ESBS) de Strasbourg (France) and a
PhD in Molecular Biology & Biochemistry specialized in Virology from the University
of Strasbourg co-directed with the University of Thessaly (Greece).
anissa.boumlic@merckgroup.comAnissa Boumlic-Courtade
Merck Group, France